Reporter Account  Create New Account  Login!
Search :
QUICK LINKS : Art & Entertainment Automotive Blogging & Social Media Business Computer Design Education Environment Events / Trade Shows  
For Press Release Writing
Promote Your Events
Post Your Story for FREE!
Increase Sales in Just 69 secs!
Startup Funding Conference
Platform for Startups
Press Release Details    
Add to Favorites  Mail to a Friend Print Page   Share This News Rate
Save This Listing     Stumble It          

Development of Double Barreled Antibodies against Myeloma Paving the Ways for Future Growth

“Bi-specific antibody development targeting other antigens such as CD387, CD1388, CS-110, and FcRH511 have again fuelled interest in Double Barreled Antibodies industry”, says RNCOS.

The first bi-specific antibody against myeloma targeting Wue-1 on plasma cells was developed as scFv BiTE antibody. This development demonstrated killing of myeloma cell lines and primary myeloma cells in vitro at low temperature. Since then, bi-specific antibodies targeting other antigens such as CD387, CD1388, CS-110, and FcRH511 have been developed.

According to a new research report by RNCOS entitled, “Global Double Barreled Antibodies Drug Sales (BLINCYTO & Removab), Pipeline Analysis (By Phase, Technology, and Indication), & Global Market Forecasts 2022”, other strategies such as engagement of NK cells with NKG2D receptor have been explored. Currently, B-cell maturation antigen (BCMA, CD269), primarily expressed on plasma cells and involved in pro-survival signaling, has been a target with high preclinical development activities. Moreover, there are many forms of anti-BCMA bi-specific antibodies in preclinical development. Ab-957 is a BCMAxCD3 IgG like bi-specific antibody manufactured using Genmab DuoBody Technology by Janssen. This technology makes use of half-molecule exchange to generate bispecifics that are close in proximity to their natural format though with low immunogenicity. Ab-957 is being developed for Phase 1 clinical trial testing.

Furthermore, EM801 and EM901 (ENgMab/Celgene) are also IgG based antibodies that are bivalent to BCMA and monovalent to CD3. Synergy is seen in in-vitro myeloma cell lysis when EM901 is given in combination with lenalidomide, daratumumab, and anti-PD1 antibody. Pfizer also has developed a fully human IgG anti-BCMAxCD3 bispecific antibody.

One of the BiTE antibodies furthest along in clinical trial development is BI 836909 by Amgen. BI 836909 is a tandem scFv to BCMA (N-terminal) and CD3 (C-terminal). In vitro testing showed that this BiTE antibody activates T cells in a BCMA dependent manner and induces T cell proliferation and myeloma cell apoptosis in both myeloma cells. A Phase 1 clinical trial is concomitantly under way testing BI 836909 in patients with relapsed myeloma. This is a multicenter study being conducted in France and Germany and planned data analysis is to be done in Summer 2017. In lieu of such advancements in bi-specific antibody development the overall market for double barreled antibodies is expected to flourish in future.

For FREE SAMPLE of this report visit:

Check Related REPORTS on:


RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.  

Contact Information

  • Name: Shushmul Maheshwari

    Company: RNCOS E-Services Pvt. Ltd.

    Telphone: 24700-24700-4224700 , 120-4224700

    Address: G-199,